Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

IVIG prophylaxis led to improvements in infection-free survival as well as progression free and overall survival in patients ...

Including 24-hour urine testing in multiple myeloma response assessments is largely unnecessary, a new phase 3 trial suggests ...

Treatment for multiple myeloma has evolved significantly, with long-term survival increasingly within reach for many patients ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...

The three-year OS rate was 74% in the belantamab mafodotin combination arm and 60% in the daratumumab combination arm. The ...

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...